A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850
Clinical Trial Grant
Administered By
Pediatrics, Medical Genetics
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
October 8, 2024
End Date
June 1, 2027
Administered By
Pediatrics, Medical Genetics
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
October 8, 2024
End Date
June 1, 2027